Yong Fang

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Jie Wang, Caicun Zhou, Wenxiu Yao et al. · The Lancet Oncology · 2022 · 361 citations

Oncology, Pharmacology, Bronchial Neoplasm +5

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency

Chaoyang Sun, Jun‐Jie Yin, Yong Fang et al. · Cancer Cell · 2018 · 295 citations · Full text

Homologous Recombination Deficiency, Engineering, Molecular Biology +6

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

Shengxiang Ren, Jianhua Chen, Xingxiang Xu et al. · Journal of Thoracic Oncology · 2021 · 293 citations

Camrelizumab Plus Carboplatin, Medicine, Advanced Squamous Nsclc +8

Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in <i>RAS</i> mutant cancers

Chaoyang Sun, Yong Fang, Jun‐Jie Yin et al. · Science Translational Medicine · 2017 · 231 citations · Full text

Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy

Yong Fang, Daniel J. McGrail, Chaoyang Sun et al. · Cancer Cell · 2019 · 231 citations · Full text

Clinical Therapeutic, Medicine, Pharmacotherapy +4